NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Duarte A, Mebrahtu T, Goncalves PS, et al. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2017 Nov. (Health Technology Assessment, No. 21.64.)
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Show detailsThe potential extra cost to the NHS of providing adalimumab, etanercept or ustekinumab to children and young people with moderate to severe plaque psoriasis is largely uncertain, given the paucity of evidence on the health-care resource use specific to this population and the uncertainties in the effectiveness evidence base. The resource use associated with BSC in terms of the expected number of hospitalisations per annum was identified as a key area of uncertainty, as in previous TAs of psoriasis in adults. Reducing uncertainty at this level would allow a more accurate assessment of the potential impact on the consumption of NHS resources of providing biological treatment to children and young people with moderate to severe plaque psoriasis.
- Assessment of factors relevant to the NHS and other parties - Adalimumab, etaner...Assessment of factors relevant to the NHS and other parties - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
Your browsing activity is empty.
Activity recording is turned off.
See more...